[ad_1]
Butantan seeks to develop alternative vaccine against covid-19
Date: 05/05/2020
Archive – Agência Brasil
Bruno Bocchini – Repórter da Agência Brasil – São Paulo
Investigators of the Butantan Institute, in the capital of São Paulo, are using innovative biotechnology techniques to develop an alternative vaccine against covid-19. The institute hopes that a new board will serve as a species of plane B, as the feitas vacinas traditional model hair, in some countries, have not been satisfactory.
Segundo or Butantan, a vaccine that the institute is developing uses a mechanism used by some bacteria to deceive or the human immune system: they produce small balls, or vesicles, feites with material from their membranes to trap defense cells. This form, or immune system, begins to attack the Bolhas as well, diminishing aggression against the bacteria.
The researchers of the institute think of fazer or mesmo, manufacturing these bags in the laboratory, but instead of using bacterial membranes, they are going to couple the surface protein vesicles of the novo coronavirus. Assim, in contact with the defense system, as bolhas will create a non-organism immunological memory, stimulating the production of specific antibodies against or coronavirus.
According to Butantan, the vesicles are very immunogenic, ou seja, have a high capacity to stimulate the immune system or enter into contact with the body. Second or high school, recent studies have shown that they have the greatest ability to activate defense cells in the body.
“Not the whole world, and not here, too, Brazil, different techniques are being tested. Muitas delas têm as a base or that was being developed for other viruses, such as what caused or happened to Sars [síndrome respiratória aguda grave] in 2001. We hope it works, more or less, that no one knows how to protect it. At this time of a pandemic, you must not try different strategies. It will not take longer for us to get out, but those who are being tested will not work, we will never have plans B, C or D ”, highlighted researcher Luciana Cezar Cerqueira Leite, from the Development Laboratory of Vacinas do Instituto Butantan.
The investigation is being supported by the Fundação de Amparo à Pesquisa do Estado de São Paulo (Fapesp).
Compartilhar:
[ad_2]
